Kadcyla Trastuzumab Emtansine 160mg Injection
Kadcyla Trastuzumab Emtansine 160mg Injection is an advanced targeted therapy designed for the treatment of HER2-positive breast cancer. It combines the HER2-targeted properties of trastuzumab with the cytotoxic agent DM1, offering a more effective treatment by delivering the chemotherapy directly to cancer cells.
Contact Details to Place Order:
💬 WhatsApp: +91 9730316395
📞 Phone: +91 9730316395
📧 Email: info@globmedindia.com
🌐 Website: https://globmedindia.com
Composition and Content
- Active Ingredient: Trastuzumab emtansine 160mg
- Excipients: Trehalose dihydrate, histidine, polysorbate 20, sodium chloride, and water for injection
How to Use & Dosage
- Administered via intravenous infusion over 30–90 minutes
- Recommended dose: 3.6 mg/kg every 3 weeks
- Dose adjustments may be required based on liver function and blood cell counts
- Should be administered under supervision of a qualified healthcare professional
Uses and Treatments
- Indicated for HER2-positive metastatic or locally advanced breast cancer
- Used in patients previously treated with trastuzumab and a taxane
- Helps in reducing tumor progression and improving patient survival rates
Advantages
- Targeted delivery reduces exposure of healthy cells to cytotoxic effects
- Convenient dosing schedule (once every 3 weeks)
- Improves overall response rate and progression-free survival in HER2-positive breast cancer
Storage Conditions
- Store at 2°C–8°C (refrigerated)
- Protect from light
- Do not freeze
- Use immediately after preparation or as per manufacturer’s guidelines
Alternative Indian Brands
- Kadcyla Biosimilars: Emtrast, Trazimab-DM1, Trastadex 160mg Injection
- Always consult a healthcare professional before switching to a biosimilar
